By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


NeuroVive Pharmaceutical AB 

Biomedical Center

Sölvegatan 19    SE-221 84 Lund  Sweden
Phone: 46-0-46-288-0110 Fax: 46-0-46-888-8348


NeuroVive Pharmaceutical is a pioneer in mitochondrial research and development. The focus is on developing drug candidates that maintain mitochondrial integrity and improves their function for indications with unmet medical needs. Research and development is conducted both in-house and in collaboration with renowned international partners.




Founder: Eskil Elmér

CEO: Erik Kinnman

CSO and Founder: Eskil Elmér

Key Statistics

Ownership: Public

Web Site: NeuroVive
Symbol: NVP


Company News
NeuroVive (NVP) And Yungjin Pharmaceutical Company Ltd. Start Clinical Development In Genetic Mitochondrial Disease 6/27/2017 10:03:02 AM
NeuroVive (NVP) Receives Research Grant From Vinnova For Development Of The NVP015 Genetic Mitochondrial Disease Project 6/1/2017 7:02:27 AM
NeuroVive (NVP) To Continue Neurostat Clinical Development After Positive Outcome In Preclinical And Clinical TBI Studies 5/23/2017 7:12:10 AM
NeuroVive (NVP) Interim Report January - March 2017 5/18/2017 9:36:10 AM
NeuroVive (NVP) In-Licenses A Genetic Mitochondrial Disease Clinical Stage Project From Yungjin Pharmaceutical Company Ltd. 5/2/2017 6:31:37 AM
NeuroVive (NVP) Presents Preclinical Findings Of NV556 In NASH Showing Confirmatory Anti-Fibrotic Effects 4/20/2017 6:39:24 AM
Number Of Shares And Votes In NeuroVive (NVP) 3/31/2017 8:57:22 AM
NeuroVive (NVP) Publishes 2016 Annual Report 3/23/2017 9:34:09 AM
Notice Of Annual General Meeting Of Shareholders In NeuroVive (NVP) 3/23/2017 8:30:38 AM
NeuroVive (NVP) Appoints Recognized Scientific Advisors And Enters Research Agreements In NASH And Hepatocellular Carcinoma 2/22/2017 6:46:44 AM